BioCentury
ARTICLE | Financial News

Unum plans NASDAQ IPO

March 9, 2018 6:12 PM UTC

Immuno-oncology company Unum Therapeutics Inc. (Cambridge, Mass.) filed on March 2 to raise up to $86.3 million in an IPO on NASDAQ underwritten by Morgan Stanley, Cowen and Wedbush PacGrow.

Founded in 2014, Unum is developing cancer immunotherapies based on its antibody-coupled T cell receptor (ACTR) technology. Lead program ACTR087 is an antibody-targeted tumor cell killing (ATTCK) therapy using a combination of autologous T-lymphocytes engineered to express a CD16-41BB-CD3zeta chimeric receptor administered with rituximab, a mAb targeting CD20 (see BioCentury, Oct. 27, 2014)...

BCIQ Company Profiles

Cogent Biosciences Inc.